Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Luca Mologni et al.|Molecular Cancer Therapeutics|2016Cited by 317
Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrierClara Albanese, Marina Ciomei, Rachele Alzani et al.|British Journal of Pharmacology|2013Cited by 21
Supplementary Materials and Methods from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Unknown|2023Cited by 0
Supplementary Materials and Methods from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Patrizia Banfi et al.|Unknown|2023Cited by 0
Supplementary Figures 1-6 and Tables 1-2 from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Unknown|2023Cited by 0